An fascinating research from Miquel Serra-Burriel et al. (2024) examines the influence of genericization on drug costs throughout 8 high-income nations (Australia, Canada, France, Germany, Japan, Switzerland, UK, and US). The authors used 2011-2020 IQVIA MIDAS information throughout 505 novel originator medication. They discovered that:
Worth decreases have been statistically vital over the 8 years after patent expiration, with the quickest worth declines noticed within the US: 32% (95% CI, 24%-39%) in 12 months 1 after patent expiration and 82% (95% CI, 71%-89%) within the 8 years after patent expiration. Estimates for different nations ranged from a lower of 64% in Australia to 18% in Switzerland within the 8 years after expiration. The associated fee-effectiveness simulation mannequin indicated that not accounting for generic entry into the market could produce biased incremental cost-effectiveness ratios of 40% to −40%, relying on the state of affairs.
You may learn the complete article right here.
